Key result
Low baseline mean platelet volume was a significant predictor of the combined safety endpoint, which occurred in 30.9% of patients at 30 days following TF-TAVI.
Why the study?
Does low baseline mean platelet volume predict combined safety endpoints and vascular/bleeding complications in patients undergoing TF-TAVI?
Cohort (n=330)
Does low baseline mean platelet volume predict combined safety endpoints and vascular/bleeding complications in patients undergoing TF-TAVI?
Low baseline mean platelet volume serves as a novel, significant predictor of combined safety endpoints, major vascular complications, and life-threatening bleeding following TF-TAVI.
May support closer monitoring after TF-TAVI in patients with low baseline mean platelet volume; leaves open its role in risk stratification pending validation.
BACKGROUND: Vascular and bleeding complications remain important complications in patients undergoing percutaneous transfemoral transcatheter aortic valve implantation (TF-TAVI). Platelets play an important role in bleeding events. Mean platelet volume (MPV) is an indicator of platelet activation. The objective of this study was to assess whether low MPV is an indicator of major vascular and bleeding complications following TF-TAVI. METHODS: A retrospective cohort study of 330 subjects undergoing TF-TAVI implantation was performed. The primary study endpoint was the occurrence of combined safety endpoint (CSEP); secondary endpoints included major vascular complications and life-threatening bleeding. Endpoints were defined according to Valve Academic Research Consortium 2. RESULTS: The CSEP at 30 days was reached in 30.9%; major vascular complications were observed in 14.9% while life-threatening bleeding occurred in 20.6%. Logistic Euroscore and MPV were independent predictors of CSEP. Predictors of vascular complications were female sex, previous myocardial infarction, red blood cell distribution width (RDW), and MPV while predictors of life-threatening bleeding were peripheral arterial disease, RDW, and MPV. CONCLUSION: A low baseline MPV was shown for the first time to be a significant predictor of CSEP, major vascular complications, and life-threatening bleeding following TF-TAVI.
No takes yet. Share an insight, caveat, or question.
Magri et al. (2013) conducted a cohort in Percutaneous transfemoral transcatheter aortic valve implantation (TF-TAVI) (n=330). Low baseline mean platelet volume (MPV) was evaluated on Combined safety endpoint (CSEP) at 30 days. Low baseline mean platelet volume was a significant predictor of the combined safety endpoint, which occurred in 30.9% of patients at 30 days following TF-TAVI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: